iBio (IBIO) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
iBio (IBIO) has outperformed Rani Therapeutics (RANI) over the past year, losing 23.8% versus a loss of 68.6%. Over five years, RANI leads with a -98.3% price change compared with -99.8% for IBIO. Rani Therapeutics is the larger company by market cap ($59.0 million vs $56.4 million), about 1.0 times the size.
Rani Therapeutics converts more of its revenue into profit, with a net margin of -1817.1% versus -33044.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBIO | RANI |
|---|---|---|
| Share price | $0.8001 | $0.5111 |
| Market cap | $56.37M | $59.03M |
| 1-day change | -0.11% | -11.97% |
| YTD return | -58.54% | -62.14% |
| 1-year return | -23.80% | -68.64% |
| 5-year return | -99.76% | -98.34% |
| EPS (TTM) | $-0.27 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $100.00K | $1.63M |
| Revenue growth (YoY) | -75.00% | +58.85% |
| Net income (latest FY) | $-33.04M | $-29.67M |
| Operating margin | -35141.00% | -2345.99% |
| Net margin | -33044.00% | -1817.09% |
| 52-week high | $3.82 | $1.69 |
| 52-week low | $0.68 | $0.502 |
| Distance from 52-week high | -79.05% | -69.76% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +611.16% | +1308.73% |
| Average volume | 678.91K | 545.67K |
| Shares outstanding | 70.46M | 115.49M |
| Employees | 23 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed RANI by 44.8 percentage points over the past year.
- Rani Therapeutics is more profitable, keeping -1817.1 cents of every revenue dollar as net income versus -33044.0 cents for iBio.
- Rani Therapeutics grew revenue faster in its latest fiscal year (+58.85% vs -75.00%).
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
IBIO vs RANI FAQ
Which is bigger, iBio or Rani Therapeutics?
Rani Therapeutics (RANI) is larger, with a market capitalization of $59.03M compared with $56.37M for iBio (IBIO).
Which stock has performed better over the past year, IBIO or RANI?
IBIO returned -23.80% over the past 12 months, compared with -68.64% for RANI (price return, excluding dividends). Past performance does not predict future results.
Are iBio and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.